These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2400946

  • 1. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
    Kemeny NE, Schneider A, Martin DS.
    Cancer Invest; 1990; 8(2):263-4. PubMed ID: 2400946
    [No Abstract] [Full Text] [Related]

  • 2. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
    Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, Sawyer R.
    Cancer; 1993 Mar 01; 71(5):1875-81. PubMed ID: 8448752
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
    Ragnhammar P, Blomgren H.
    Med Oncol; 1995 Sep 01; 12(3):187-201. PubMed ID: 8852401
    [No Abstract] [Full Text] [Related]

  • 5. Biochemical modulation of 5-fluorouracil by PALA.
    O'Dwyer PJ.
    Cancer Invest; 1990 Sep 01; 8(2):261-2. PubMed ID: 2400945
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biomodulation of Fluorouracil in colorectal cancer.
    Ardalan B, Luis R, Jaime M, Franceschi D.
    Cancer Invest; 1998 Sep 01; 16(4):237-51. PubMed ID: 9589033
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Kemeny N, Schneider A, Martin DS, Colofiore J, Sawyer RC, Derby S, Salvia B.
    Cancer Res; 1989 Aug 15; 49(16):4636-9. PubMed ID: 2472883
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 15. Cancer chemotherapy: past is prologue.
    Martin DS.
    Mt Sinai J Med; 1985 Jun 15; 52(6):426-34. PubMed ID: 3875021
    [No Abstract] [Full Text] [Related]

  • 16. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B, Sridhar KS, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, Livingstone A.
    Cancer; 1991 Sep 15; 68(6):1242-6. PubMed ID: 1873776
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
    Köhne-Wömpner CH, Schmoll HJ, Harstrick A, Rustum YM.
    Semin Oncol; 1992 Apr 15; 19(2 Suppl 3):105-25. PubMed ID: 1373004
    [Abstract] [Full Text] [Related]

  • 20. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI, Oster W, Kerr DJ, Canney PA, Yosef H, Steward WP, Kaye SB, Cassidy J.
    Eur J Cancer; 1994 Apr 15; 30A(7):950-5. PubMed ID: 7946590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.